Incyte
(NASDAQ:INCY)
$78.76
0.50[0.64%]
Last update: 12:30PM (Delayed 15-Minutes)
Get Real Time Here
Day Range78.22 - 7952 Wk Range65.07 - 84.86Open / Close78.3 / -Float / Outstanding183.6M / 222.5M
Vol / Avg.159.4K / 1.4MMkt Cap17.5BP/E19.8650d Avg. Price72.18
Div / Yield-Payout Ratio-Total Float183.6MEPS0.51

Incyte Stock (NASDAQ:INCY), Quotes and News Summary

Incyte Stock (NASDAQ: INCY) stock price, news, charts, stock research, profile.

Loading...
Day Range78.22 - 7952 Wk Range65.07 - 84.86Open / Close78.3 / -Float / Outstanding183.6M / 222.5M
Vol / Avg.159.4K / 1.4MMkt Cap17.5BP/E19.8650d Avg. Price72.18
Div / Yield-Payout Ratio-Total Float183.6MEPS0.51
Business Wire - Nov 17, 2022, 8:00AM
Business Wire - Oct 11, 2022, 8:00AM
Business Wire - Oct 4, 2022, 8:00AM
Business Wire - Aug 23, 2022, 8:00AM
Business Wire - Jul 12, 2022, 8:00AM
Business Wire - May 24, 2022, 8:00AM
Business Wire - May 4, 2022, 4:15PM
Business Wire - Apr 12, 2022, 8:00AM
InvestorPlace - Nov 4, 2022, 2:22PM
Seeking Alpha - Nov 2, 2022, 4:36PM
Seeking Alpha - Nov 2, 2022, 4:15PM
InvestorsObserver - Nov 1, 2022, 10:54AM
Seeking Alpha - Oct 31, 2022, 11:21AM
TalkMarkets - Oct 4, 2022, 8:52AM
Seeking Alpha - Oct 3, 2022, 6:40AM
StockNews - Sep 23, 2022, 5:48AM
InvestorsObserver - Sep 13, 2022, 3:19PM
StockNews - Sep 6, 2022, 4:59AM
TipRanks - Sep 5, 2022, 9:46PM
Sector: Health Care.Industry: Biotechnology
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-02-07
REV
Q3 2022Est.ActualSurprise
EPS0.7400.600 -0.1400
REV848.190M823.303M-24.887M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Incyte (INCY) stock?

A

You can purchase shares of Incyte (NASDAQ: INCY) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Incyte (INCY) stock?

A

The latest price target for Incyte (NASDAQ: INCY) was reported by RBC Capital on Wednesday, November 2, 2022. The analyst firm set a price target for 82.00 expecting INCY to rise to within 12 months (a possible 4.11% upside). 16 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Incyte (INCY)?

A

The stock price for Incyte (NASDAQ: INCY) is $78.76 last updated Today at November 28, 2022, 5:30 PM UTC.

Q

Does Incyte (INCY) pay a dividend?

A

There are no upcoming dividends for Incyte.

Q

When is Incyte (NASDAQ:INCY) reporting earnings?

A

Incyte’s Q4 earnings are confirmed for Tuesday, February 7, 2023.

Q

Is Incyte (INCY) going to split?

A

There is no upcoming split for Incyte.

Q

What sector and industry does Incyte (INCY) operate in?

A

Incyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.